4basebio Statistics

Total Valuation

4basebio has a market cap or net worth of EUR 178.32 million. The enterprise value is 155.38 million.

Market Cap	178.32M
Enterprise Value	155.38M

Important Dates

The last earnings date was Wednesday, June 11, 2025.

Earnings Date	Jun 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	15.48M
Shares Outstanding	n/a
Shares Change (YoY)	+6.47%
Shares Change (QoQ)	+6.41%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	5.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	158.05
PB Ratio	5.59
P/TBV Ratio	5.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-10.42
EV / Sales	142.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.23

Financial Position

The company has a current ratio of 11.30, with a Debt / Equity ratio of 0.58.

Current Ratio	11.30
Quick Ratio	11.08
Debt / Equity	0.58
Debt / EBITDA	n/a
Debt / FCF	-1.33
Interest Coverage	-17.01

Financial Efficiency

Return on equity (ROE) is -95.28% and return on invested capital (ROIC) is -31.01%.

Return on Equity (ROE)	-95.28%
Return on Assets (ROA)	-28.23%
Return on Invested Capital (ROIC)	-31.01%
Return on Capital Employed (ROCE)	-30.85%
Revenue Per Employee	10,257
Profits Per Employee	-135,577
Employee Count	110
Asset Turnover	0.03
Inventory Turnover	0.86

Taxes

Income Tax	-388,164
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.25% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-38.25%
50-Day Moving Average	12.53
200-Day Moving Average	14.15
Relative Strength Index (RSI)	25.92
Average Volume (20 Days)	412

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, 4basebio had revenue of EUR 1.13 million and -14.91 million in losses. Loss per share was -1.14.

Revenue	1.13M
Gross Profit	761,818
Operating Income	-15.47M
Pretax Income	-15.30M
Net Income	-14.91M
EBITDA	-14.56M
EBIT	-15.47M
Loss Per Share	-1.14

Full Income Statement

Balance Sheet

The company has 42.12 million in cash and 18.40 million in debt, giving a net cash position of 23.72 million.

Cash & Cash Equivalents	42.12M
Total Debt	18.40M
Net Cash	23.72M
Net Cash Per Share	n/a
Equity (Book Value)	31.90M
Book Value Per Share	2.06
Working Capital	40.66M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.99 million and capital expenditures -842,836, giving a free cash flow of -13.83 million.

Operating Cash Flow	-12.99M
Capital Expenditures	-842,836
Free Cash Flow	-13.83M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	67.52%
Operating Margin	-1,371.17%
Pretax Margin	-1,356.27%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

4basebio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.47%
Shareholder Yield	n/a
Earnings Yield	-8.36%
FCF Yield	-7.76%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

4basebio has an Altman Z-Score of 3.79 and a Piotroski F-Score of 3.

Altman Z-Score	3.79
Piotroski F-Score	3